GMP compliant iPSC lines and immune-oncology platform for allogeneic cell therapy

Written by Catalent
Cancer Cell therapy GMP iPSCs Stem cells

This poster outlines a GMP manufacturing process for the creation of human induced pluripotent stem cells for use in allogeneic cell therapy applications.

This poster is part of the RegMedNet Spotlight on iPSCs. Click here to view the full feature and discover expert insights on this.

ISCT 2023 NK poster draft final DTK

This content was provided by Catalent.